In a study conducted by the Harvard Stem Cell Institute at Massachusetts General Hospital, a research team led by Dr. Khalid Shah, MS, PhD, utilized Mesenchymal Stem Cells (MSCs) to facilitate the delivery of a tumor-killing virus into an animal model afflicted with brain cancer. The virus was loaded onto the MSCs and encapsulated into a biocompatible gel that, when injected into the models, resulted in a higher viral efficacy and increased survival rate.
As reported in a recent article in the New York Times, researchers from the National Cancer Institute have developed an immune system treatment for a woman afflicted with cholangiocarcinoma (bile-duct cancer) utilizing her own stem cells. The scientists, led by Dr. Steven A Rosenberg, identified T-cells in the woman’s immune system that specifically attacked the cancerous cells in her body. They then used her stem cells to grow billions of these T-cells in a laboratory, and then infused the T-cells back into her bloodstream. After 18 months of the treatment, known as adoptive cell therapy, the woman experienced considerable reduction of tumor size and quantity.